Therapeutic efficacy of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant and macrolide-sensitive Mycoplasma pneumoniae pneumonia in pediatric patients
To clarify therapeutic effects of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae (MRMP) pneumonia and against macrolide-sensitive Mycoplasma pneumoniae (MSMP) pneumonia in pediatric patients. A prospective, multicenter observational study...
Saved in:
| Published in | PloS one Vol. 12; no. 3; p. e0173635 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Public Library of Science
13.03.2017
Public Library of Science (PLoS) |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | To clarify therapeutic effects of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae (MRMP) pneumonia and against macrolide-sensitive Mycoplasma pneumoniae (MSMP) pneumonia in pediatric patients.
A prospective, multicenter observational study was conducted from July 2013 to August 2015. The therapeutic effects of azithromycin, clarithromycin, minocycline and tosufloxacin were evaluated in 59 patients with pneumonia caused by MRMP and in 50 patients with pneumonia caused by MSMP. In vitro activities of antimicrobial agents against isolates of Mycoplasma pneumoniae were also measured.
Mean durations of fever following commencement of treatment in patients infected with MRMP and MSMP were 5.2 and 1.9 days, respectively (log-rank test, P < 0.0001). Among patients infected with MRMP, mean durations of fever were 4.6, 5.5, 1.0 and 7.5 days for patients treated with azithromycin, clarithromycin, minocycline and tosufloxacin, respectively (log-rank test, P < 0.0001). Among patients infected with MSMP, mean durations of fever were 2.5, 1.7, 0.9 and 4.3 days for patients treated with azithromycin, clarithromycin, minocycline and tosufloxacin, respectively (log-rank test, P = 0.0162). The MIC90s of azithromycin and clarithromycin among the 27 isolates of MRMP were 64 and 256 μg/ml, respectively, and those among the 23 isolates of MSMP were <0.000125 and 0.001 μg/ml, respectively. The MIC90s of minocycline and tosufloxacin among the 27 isolates of MRMP were 1.0 and 0.25 μg/ml, respectively, and those among the 23 isolates of MSMP were 1.0 and 0.5 μg/ml, respectively.
Both minocycline and tosufloxacin showed good in vitro activities against MRMP. Minocycline, but not tosufloxacin, shortened the duration of fever in pediatric patients infected with MRMP compared to the duration of fever in patients treated with macrolides. |
|---|---|
| AbstractList | Objective To clarify therapeutic effects of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae (MRMP) pneumonia and against macrolide-sensitive Mycoplasma pneumoniae (MSMP) pneumonia in pediatric patients. Methods A prospective, multicenter observational study was conducted from July 2013 to August 2015. The therapeutic effects of azithromycin, clarithromycin, minocycline and tosufloxacin were evaluated in 59 patients with pneumonia caused by MRMP and in 50 patients with pneumonia caused by MSMP. In vitro activities of antimicrobial agents against isolates of Mycoplasma pneumoniae were also measured. Results Mean durations of fever following commencement of treatment in patients infected with MRMP and MSMP were 5.2 and 1.9 days, respectively (log-rank test, P < 0.0001). Among patients infected with MRMP, mean durations of fever were 4.6, 5.5, 1.0 and 7.5 days for patients treated with azithromycin, clarithromycin, minocycline and tosufloxacin, respectively (log-rank test, P < 0.0001). Among patients infected with MSMP, mean durations of fever were 2.5, 1.7, 0.9 and 4.3 days for patients treated with azithromycin, clarithromycin, minocycline and tosufloxacin, respectively (log-rank test, P = 0.0162). The MIC90s of azithromycin and clarithromycin among the 27 isolates of MRMP were 64 and 256 [mu]g/ml, respectively, and those among the 23 isolates of MSMP were <0.000125 and 0.001 [mu]g/ml, respectively. The MIC90s of minocycline and tosufloxacin among the 27 isolates of MRMP were 1.0 and 0.25 [mu]g/ml, respectively, and those among the 23 isolates of MSMP were 1.0 and 0.5 [mu]g/ml, respectively. Conclusion Both minocycline and tosufloxacin showed good in vitro activities against MRMP. Minocycline, but not tosufloxacin, shortened the duration of fever in pediatric patients infected with MRMP compared to the duration of fever in patients treated with macrolides. To clarify therapeutic effects of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae (MRMP) pneumonia and against macrolide-sensitive Mycoplasma pneumoniae (MSMP) pneumonia in pediatric patients. A prospective, multicenter observational study was conducted from July 2013 to August 2015. The therapeutic effects of azithromycin, clarithromycin, minocycline and tosufloxacin were evaluated in 59 patients with pneumonia caused by MRMP and in 50 patients with pneumonia caused by MSMP. In vitro activities of antimicrobial agents against isolates of Mycoplasma pneumoniae were also measured. Mean durations of fever following commencement of treatment in patients infected with MRMP and MSMP were 5.2 and 1.9 days, respectively (log-rank test, P < 0.0001). Among patients infected with MRMP, mean durations of fever were 4.6, 5.5, 1.0 and 7.5 days for patients treated with azithromycin, clarithromycin, minocycline and tosufloxacin, respectively (log-rank test, P < 0.0001). Among patients infected with MSMP, mean durations of fever were 2.5, 1.7, 0.9 and 4.3 days for patients treated with azithromycin, clarithromycin, minocycline and tosufloxacin, respectively (log-rank test, P = 0.0162). The MIC90s of azithromycin and clarithromycin among the 27 isolates of MRMP were 64 and 256 [mu]g/ml, respectively, and those among the 23 isolates of MSMP were <0.000125 and 0.001 [mu]g/ml, respectively. The MIC90s of minocycline and tosufloxacin among the 27 isolates of MRMP were 1.0 and 0.25 [mu]g/ml, respectively, and those among the 23 isolates of MSMP were 1.0 and 0.5 [mu]g/ml, respectively. Both minocycline and tosufloxacin showed good in vitro activities against MRMP. Minocycline, but not tosufloxacin, shortened the duration of fever in pediatric patients infected with MRMP compared to the duration of fever in patients treated with macrolides. To clarify therapeutic effects of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae (MRMP) pneumonia and against macrolide-sensitive Mycoplasma pneumoniae (MSMP) pneumonia in pediatric patients.OBJECTIVETo clarify therapeutic effects of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae (MRMP) pneumonia and against macrolide-sensitive Mycoplasma pneumoniae (MSMP) pneumonia in pediatric patients.A prospective, multicenter observational study was conducted from July 2013 to August 2015. The therapeutic effects of azithromycin, clarithromycin, minocycline and tosufloxacin were evaluated in 59 patients with pneumonia caused by MRMP and in 50 patients with pneumonia caused by MSMP. In vitro activities of antimicrobial agents against isolates of Mycoplasma pneumoniae were also measured.METHODSA prospective, multicenter observational study was conducted from July 2013 to August 2015. The therapeutic effects of azithromycin, clarithromycin, minocycline and tosufloxacin were evaluated in 59 patients with pneumonia caused by MRMP and in 50 patients with pneumonia caused by MSMP. In vitro activities of antimicrobial agents against isolates of Mycoplasma pneumoniae were also measured.Mean durations of fever following commencement of treatment in patients infected with MRMP and MSMP were 5.2 and 1.9 days, respectively (log-rank test, P < 0.0001). Among patients infected with MRMP, mean durations of fever were 4.6, 5.5, 1.0 and 7.5 days for patients treated with azithromycin, clarithromycin, minocycline and tosufloxacin, respectively (log-rank test, P < 0.0001). Among patients infected with MSMP, mean durations of fever were 2.5, 1.7, 0.9 and 4.3 days for patients treated with azithromycin, clarithromycin, minocycline and tosufloxacin, respectively (log-rank test, P = 0.0162). The MIC90s of azithromycin and clarithromycin among the 27 isolates of MRMP were 64 and 256 μg/ml, respectively, and those among the 23 isolates of MSMP were <0.000125 and 0.001 μg/ml, respectively. The MIC90s of minocycline and tosufloxacin among the 27 isolates of MRMP were 1.0 and 0.25 μg/ml, respectively, and those among the 23 isolates of MSMP were 1.0 and 0.5 μg/ml, respectively.RESULTSMean durations of fever following commencement of treatment in patients infected with MRMP and MSMP were 5.2 and 1.9 days, respectively (log-rank test, P < 0.0001). Among patients infected with MRMP, mean durations of fever were 4.6, 5.5, 1.0 and 7.5 days for patients treated with azithromycin, clarithromycin, minocycline and tosufloxacin, respectively (log-rank test, P < 0.0001). Among patients infected with MSMP, mean durations of fever were 2.5, 1.7, 0.9 and 4.3 days for patients treated with azithromycin, clarithromycin, minocycline and tosufloxacin, respectively (log-rank test, P = 0.0162). The MIC90s of azithromycin and clarithromycin among the 27 isolates of MRMP were 64 and 256 μg/ml, respectively, and those among the 23 isolates of MSMP were <0.000125 and 0.001 μg/ml, respectively. The MIC90s of minocycline and tosufloxacin among the 27 isolates of MRMP were 1.0 and 0.25 μg/ml, respectively, and those among the 23 isolates of MSMP were 1.0 and 0.5 μg/ml, respectively.Both minocycline and tosufloxacin showed good in vitro activities against MRMP. Minocycline, but not tosufloxacin, shortened the duration of fever in pediatric patients infected with MRMP compared to the duration of fever in patients treated with macrolides.CONCLUSIONBoth minocycline and tosufloxacin showed good in vitro activities against MRMP. Minocycline, but not tosufloxacin, shortened the duration of fever in pediatric patients infected with MRMP compared to the duration of fever in patients treated with macrolides. OBJECTIVE:To clarify therapeutic effects of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae (MRMP) pneumonia and against macrolide-sensitive Mycoplasma pneumoniae (MSMP) pneumonia in pediatric patients. METHODS:A prospective, multicenter observational study was conducted from July 2013 to August 2015. The therapeutic effects of azithromycin, clarithromycin, minocycline and tosufloxacin were evaluated in 59 patients with pneumonia caused by MRMP and in 50 patients with pneumonia caused by MSMP. In vitro activities of antimicrobial agents against isolates of Mycoplasma pneumoniae were also measured. RESULTS:Mean durations of fever following commencement of treatment in patients infected with MRMP and MSMP were 5.2 and 1.9 days, respectively (log-rank test, P < 0.0001). Among patients infected with MRMP, mean durations of fever were 4.6, 5.5, 1.0 and 7.5 days for patients treated with azithromycin, clarithromycin, minocycline and tosufloxacin, respectively (log-rank test, P < 0.0001). Among patients infected with MSMP, mean durations of fever were 2.5, 1.7, 0.9 and 4.3 days for patients treated with azithromycin, clarithromycin, minocycline and tosufloxacin, respectively (log-rank test, P = 0.0162). The MIC90s of azithromycin and clarithromycin among the 27 isolates of MRMP were 64 and 256 μg/ml, respectively, and those among the 23 isolates of MSMP were <0.000125 and 0.001 μg/ml, respectively. The MIC90s of minocycline and tosufloxacin among the 27 isolates of MRMP were 1.0 and 0.25 μg/ml, respectively, and those among the 23 isolates of MSMP were 1.0 and 0.5 μg/ml, respectively. CONCLUSION:Both minocycline and tosufloxacin showed good in vitro activities against MRMP. Minocycline, but not tosufloxacin, shortened the duration of fever in pediatric patients infected with MRMP compared to the duration of fever in patients treated with macrolides. Objective To clarify therapeutic effects of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae (MRMP) pneumonia and against macrolide-sensitive Mycoplasma pneumoniae (MSMP) pneumonia in pediatric patients. Methods A prospective, multicenter observational study was conducted from July 2013 to August 2015. The therapeutic effects of azithromycin, clarithromycin, minocycline and tosufloxacin were evaluated in 59 patients with pneumonia caused by MRMP and in 50 patients with pneumonia caused by MSMP. In vitro activities of antimicrobial agents against isolates of Mycoplasma pneumoniae were also measured. Results Mean durations of fever following commencement of treatment in patients infected with MRMP and MSMP were 5.2 and 1.9 days, respectively (log-rank test, P < 0.0001). Among patients infected with MRMP, mean durations of fever were 4.6, 5.5, 1.0 and 7.5 days for patients treated with azithromycin, clarithromycin, minocycline and tosufloxacin, respectively (log-rank test, P < 0.0001). Among patients infected with MSMP, mean durations of fever were 2.5, 1.7, 0.9 and 4.3 days for patients treated with azithromycin, clarithromycin, minocycline and tosufloxacin, respectively (log-rank test, P = 0.0162). The MIC90s of azithromycin and clarithromycin among the 27 isolates of MRMP were 64 and 256 Mg/ml, respectively, and those among the 23 isolates of MSMP were <0.000125 and 0.001 Mg/ml, respectively. The MIC90s of minocycline and tosufloxacin among the 27 isolates of MRMP were 1.0 and 0.25 Mg/ml, respectively, and those among the 23 isolates of MSMP were 1.0 and 0.5 Mg/ml, respectively. Conclusion Both minocycline and tosufloxacin showed good in vitro activities against MRMP. Minocycline, but not tosufloxacin, shortened the duration of fever in pediatric patients infected with MRMP compared to the duration of fever in patients treated with macrolides. To clarify therapeutic effects of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae (MRMP) pneumonia and against macrolide-sensitive Mycoplasma pneumoniae (MSMP) pneumonia in pediatric patients. A prospective, multicenter observational study was conducted from July 2013 to August 2015. The therapeutic effects of azithromycin, clarithromycin, minocycline and tosufloxacin were evaluated in 59 patients with pneumonia caused by MRMP and in 50 patients with pneumonia caused by MSMP. In vitro activities of antimicrobial agents against isolates of Mycoplasma pneumoniae were also measured. Mean durations of fever following commencement of treatment in patients infected with MRMP and MSMP were 5.2 and 1.9 days, respectively (log-rank test, P < 0.0001). Among patients infected with MRMP, mean durations of fever were 4.6, 5.5, 1.0 and 7.5 days for patients treated with azithromycin, clarithromycin, minocycline and tosufloxacin, respectively (log-rank test, P < 0.0001). Among patients infected with MSMP, mean durations of fever were 2.5, 1.7, 0.9 and 4.3 days for patients treated with azithromycin, clarithromycin, minocycline and tosufloxacin, respectively (log-rank test, P = 0.0162). The MIC90s of azithromycin and clarithromycin among the 27 isolates of MRMP were 64 and 256 μg/ml, respectively, and those among the 23 isolates of MSMP were <0.000125 and 0.001 μg/ml, respectively. The MIC90s of minocycline and tosufloxacin among the 27 isolates of MRMP were 1.0 and 0.25 μg/ml, respectively, and those among the 23 isolates of MSMP were 1.0 and 0.5 μg/ml, respectively. Both minocycline and tosufloxacin showed good in vitro activities against MRMP. Minocycline, but not tosufloxacin, shortened the duration of fever in pediatric patients infected with MRMP compared to the duration of fever in patients treated with macrolides. Objective To clarify therapeutic effects of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae (MRMP) pneumonia and against macrolide-sensitive Mycoplasma pneumoniae (MSMP) pneumonia in pediatric patients. Methods A prospective, multicenter observational study was conducted from July 2013 to August 2015. The therapeutic effects of azithromycin, clarithromycin, minocycline and tosufloxacin were evaluated in 59 patients with pneumonia caused by MRMP and in 50 patients with pneumonia caused by MSMP. In vitro activities of antimicrobial agents against isolates of Mycoplasma pneumoniae were also measured. Results Mean durations of fever following commencement of treatment in patients infected with MRMP and MSMP were 5.2 and 1.9 days, respectively (log-rank test, P < 0.0001). Among patients infected with MRMP, mean durations of fever were 4.6, 5.5, 1.0 and 7.5 days for patients treated with azithromycin, clarithromycin, minocycline and tosufloxacin, respectively (log-rank test, P < 0.0001). Among patients infected with MSMP, mean durations of fever were 2.5, 1.7, 0.9 and 4.3 days for patients treated with azithromycin, clarithromycin, minocycline and tosufloxacin, respectively (log-rank test, P = 0.0162). The MIC90s of azithromycin and clarithromycin among the 27 isolates of MRMP were 64 and 256 μg/ml, respectively, and those among the 23 isolates of MSMP were <0.000125 and 0.001 μg/ml, respectively. The MIC90s of minocycline and tosufloxacin among the 27 isolates of MRMP were 1.0 and 0.25 μg/ml, respectively, and those among the 23 isolates of MSMP were 1.0 and 0.5 μg/ml, respectively. Conclusion Both minocycline and tosufloxacin showed good in vitro activities against MRMP. Minocycline, but not tosufloxacin, shortened the duration of fever in pediatric patients infected with MRMP compared to the duration of fever in patients treated with macrolides. |
| Audience | Academic |
| Author | Tabata, Yuichi Koseki, Naoko Hazama, Kyosuke Nakanishi, Masanori Oba, Koji Aoyagi, Hayato Shida, Satoru Morita, Keisuke Kikuta, Hideaki Yoshioka, Mikio Ariga, Tadashi Sasaki, Satoshi Ishiguro, Nobuhisa Naito, Hiroyuki Watanabe, Toru Furuyama, Hideto Yamanaka, Tatsuru Hara, Kazuya Shibata, Mutsuo Ishizaka, Akihito Kaiho, Miki Kenri, Tsuyoshi Togashi, Takehiro Nagano, Naoko Horino, Atsuko |
| AuthorAffiliation | 18 Deparment of Pediatrics, Obihiro Kyokai Hospital, Obihiro, Hokkaido, Japan 4 Department of Biostatistics, School of Public Health, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan 14 Department of Pediatrics, Health Sciences University of Hokkaido, Sapporo, Hokkaido, Japan 16 Sumiyoshi Kodomo Clinic, Chitose, Hokkaido, Japan 6 Department of Pediatrics, Asahikawa Red Cross Hospital, Asahikawa, Hokkaido, Japan 17 Iwamizawa Pediatric and Gynecology Clinic, Iwamizawa, Hokkaido, Japan 10 Watanabe Pediatric Allergy Clinic, Sapporo, Hokkaido, Japan 2 Pediatric Clinic, Touei Hospital, Sapporo, Hokkaido, Japan 13 Deparment of Pediatrics, Japan Community Healthcare Organization Hokkaido Hospital, Sapporo, Hokkaido, Japan 20 Deparment of Pediatrics, KKR Sapporo Medical Center, Sapporo, Hokkaido, Japan Chang Gung Memorial Hospital, TAIWAN 7 Nagano Pediatric Clinic, Asahikawa, Hokkaido, Japan 19 Deparment of Pediatrics, Chitose City Hospital, Chitose, Hokkaido, Japan 21 Department of Bacter |
| AuthorAffiliation_xml | – name: 11 Yamanaka Tatsuru Pediatric Clinic, Sapporo, Hokkaido, Japan – name: Chang Gung Memorial Hospital, TAIWAN – name: 14 Department of Pediatrics, Health Sciences University of Hokkaido, Sapporo, Hokkaido, Japan – name: 13 Deparment of Pediatrics, Japan Community Healthcare Organization Hokkaido Hospital, Sapporo, Hokkaido, Japan – name: 18 Deparment of Pediatrics, Obihiro Kyokai Hospital, Obihiro, Hokkaido, Japan – name: 1 Department of Pediatrics, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan – name: 16 Sumiyoshi Kodomo Clinic, Chitose, Hokkaido, Japan – name: 2 Pediatric Clinic, Touei Hospital, Sapporo, Hokkaido, Japan – name: 15 Deparment of Pediatrics, Ebetsu Municipal Hospital, Ebetsu, Hokkaido, Japan – name: 4 Department of Biostatistics, School of Public Health, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan – name: 19 Deparment of Pediatrics, Chitose City Hospital, Chitose, Hokkaido, Japan – name: 21 Department of Bacteriology II, National Institute of Infectious Diseases, Tokyo, Japan – name: 7 Nagano Pediatric Clinic, Asahikawa, Hokkaido, Japan – name: 9 Hazama Pediatric Clinic, Muroran, Hokkaido, Japan – name: 12 Department of Pediatrics, Aiiku Hospital, Sapporo, Hokkaido, Japan – name: 17 Iwamizawa Pediatric and Gynecology Clinic, Iwamizawa, Hokkaido, Japan – name: 8 Deparment of Pediatrics, Kushiro Red Cross Hospital, Kushiro, Hokkaido, Japan – name: 5 Interfaculty Initiative in Information Studies, The University of Tokyo, Tokyo, Japan – name: 3 Hokkaido Anti–Tuberculosis Association Sapporo Fukujuji Clinic, Sapporo, Hokkaido, Japan – name: 6 Department of Pediatrics, Asahikawa Red Cross Hospital, Asahikawa, Hokkaido, Japan – name: 20 Deparment of Pediatrics, KKR Sapporo Medical Center, Sapporo, Hokkaido, Japan – name: 10 Watanabe Pediatric Allergy Clinic, Sapporo, Hokkaido, Japan |
| Author_xml | – sequence: 1 givenname: Nobuhisa orcidid: 0000-0001-8594-6345 surname: Ishiguro fullname: Ishiguro, Nobuhisa – sequence: 2 givenname: Naoko surname: Koseki fullname: Koseki, Naoko – sequence: 3 givenname: Miki surname: Kaiho fullname: Kaiho, Miki – sequence: 4 givenname: Tadashi surname: Ariga fullname: Ariga, Tadashi – sequence: 5 givenname: Hideaki surname: Kikuta fullname: Kikuta, Hideaki – sequence: 6 givenname: Takehiro surname: Togashi fullname: Togashi, Takehiro – sequence: 7 givenname: Koji surname: Oba fullname: Oba, Koji – sequence: 8 givenname: Keisuke surname: Morita fullname: Morita, Keisuke – sequence: 9 givenname: Naoko surname: Nagano fullname: Nagano, Naoko – sequence: 10 givenname: Masanori surname: Nakanishi fullname: Nakanishi, Masanori – sequence: 11 givenname: Kazuya surname: Hara fullname: Hara, Kazuya – sequence: 12 givenname: Kyosuke surname: Hazama fullname: Hazama, Kyosuke – sequence: 13 givenname: Toru surname: Watanabe fullname: Watanabe, Toru – sequence: 14 givenname: Tatsuru surname: Yamanaka fullname: Yamanaka, Tatsuru – sequence: 15 givenname: Satoshi surname: Sasaki fullname: Sasaki, Satoshi – sequence: 16 givenname: Hideto surname: Furuyama fullname: Furuyama, Hideto – sequence: 17 givenname: Mutsuo surname: Shibata fullname: Shibata, Mutsuo – sequence: 18 givenname: Satoru surname: Shida fullname: Shida, Satoru – sequence: 19 givenname: Akihito surname: Ishizaka fullname: Ishizaka, Akihito – sequence: 20 givenname: Yuichi surname: Tabata fullname: Tabata, Yuichi – sequence: 21 givenname: Hayato surname: Aoyagi fullname: Aoyagi, Hayato – sequence: 22 givenname: Hiroyuki surname: Naito fullname: Naito, Hiroyuki – sequence: 23 givenname: Mikio surname: Yoshioka fullname: Yoshioka, Mikio – sequence: 24 givenname: Atsuko surname: Horino fullname: Horino, Atsuko – sequence: 25 givenname: Tsuyoshi surname: Kenri fullname: Kenri, Tsuyoshi |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28288170$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNk9tq3DAQhk1JaQ7tG5TWUCgtdLeWZdnaXhRC6CGQEmhDb8VEGu0qyJJjySHbZ-vDVU42yW4IJfjC0uibX3PQ7GZbzjvMspekmBLakI9nfugd2GmXzNOCNLSm7Em2Q2a0nNRlQbfW1tvZbghnRcEor-tn2XbJS85JU-xkf08W2EOHQzQyR62NBLnMvc7hj4mL3rdLadyHXFro1_etcV4upTUOc3Aqjz4M2vpLSKc5zMG4EPMWZO-tUTjpMZgQwcUr-M4e0AUTzQXmP5bSdxZCC3nncGi9M4B3yzzJdqgMxD7F2UE06GJ4nj3VYAO-WP33spOvX04Ovk-Ojr8dHuwfTSSnLE5SojM9w0ZVqmGaclqh4k3NaV0h1-qUEwCtGValahTWNVN1KWdSzZSsJaN0L3t9LdtZH8Sq7kGQUaOoKCkScXhNKA9noutNC_1SeDDiyuD7uYA-VdiioFVTMS5LDYpUUMgZkUyiKuisrE8bCUnr8-q24bRFJVOiPdgN0c0TZxZi7i8EoxUvyjIJvFsJ9P58wBBFa4JEa8GhH8a4U-vrsiGPQZuGlaxmTULf3EMfLsSKmkPK1TjtU4hyFBX7FWclLzgZCzp9gEqfwtbI9J61SfYNh_cbDomJeBnnMIQgDn_9fDx7_HuTfbvGLhBsXARv0zB4FzbBV-tNue3GzSAloLoG0tMOoUd9i5BCjPN6Uy4xzqtYzWty-3TPTZoI4_WpIsb-3_kfdeVMXw |
| CitedBy_id | crossref_primary_10_1016_j_bj_2020_07_002 crossref_primary_10_1016_j_intimp_2022_109196 crossref_primary_10_1186_s12879_024_10070_3 crossref_primary_10_1016_j_jgar_2020_01_022 crossref_primary_10_1177_03000605211016376 crossref_primary_10_1371_journal_pone_0258694 crossref_primary_10_4168_aard_2020_8_2_66 crossref_primary_10_1016_j_rmed_2020_106209 crossref_primary_10_3390_jcm11102824 crossref_primary_10_1099_jmm_0_001365 crossref_primary_10_1111_apm_13514 crossref_primary_10_3201_eid2607_200017 crossref_primary_10_1007_s12519_024_00831_0 crossref_primary_10_1186_s12879_020_05356_1 crossref_primary_10_4168_aard_2020_8_2_51 crossref_primary_10_1016_j_jfma_2020_08_018 crossref_primary_10_1093_jpids_piae117 crossref_primary_10_2139_ssrn_4063512 crossref_primary_10_1007_s12098_022_04205_0 crossref_primary_10_1080_14787210_2018_1414599 crossref_primary_10_1515_labmed_2020_0096 crossref_primary_10_1007_s11908_018_0653_6 crossref_primary_10_3345_cep_2020_01305 crossref_primary_10_3346_jkms_2018_33_e268 crossref_primary_10_1128_JCM_03245_20 crossref_primary_10_1371_journal_pone_0209938 crossref_primary_10_3390_diagnostics12010048 crossref_primary_10_1159_000500970 crossref_primary_10_1007_s10096_025_05101_z crossref_primary_10_3390_antibiotics10020192 crossref_primary_10_22207_JPAM_13_1_03 crossref_primary_10_1093_jac_dkac170 crossref_primary_10_1016_j_eclinm_2024_102589 crossref_primary_10_1177_00099228251325546 crossref_primary_10_1371_journal_pone_0230338 crossref_primary_10_3390_jcm11071782 crossref_primary_10_1097_MD_0000000000023959 crossref_primary_10_12677_ACM_2022_124449 crossref_primary_10_1097_INF_0000000000004568 crossref_primary_10_1016_j_micpath_2024_106944 crossref_primary_10_1007_s00431_024_05519_1 crossref_primary_10_11150_kansenshogakuzasshi_93_643 crossref_primary_10_1186_s12879_021_06508_7 crossref_primary_10_4168_aard_2023_11_4_187 crossref_primary_10_1186_s12879_021_05830_4 crossref_primary_10_52711_0974_360X_2022_00716 crossref_primary_10_1016_j_idc_2019_07_002 crossref_primary_10_1097_INF_0000000000004041 crossref_primary_10_3201_eid2408_180081 crossref_primary_10_1186_s13052_022_01362_y crossref_primary_10_3389_fped_2021_676296 |
| Cites_doi | 10.1128/CMR.17.4.697-728.2004 10.1111/j.1365-2125.1991.tb03920.x 10.1128/AAC.00663-13 10.1128/AAC.01806-13 10.1111/j.1348-0421.2001.tb01293.x 10.1128/AAC.02060-12 10.3389/fmicb.2016.00329 10.1111/j.1440-1843.2011.02102.x 10.1093/jac/dks457 10.1097/INF.0b013e31819e3f7a 10.1111/j.1365-4632.2004.02108.x 10.1128/AAC.50.2.709-712.2006 10.1093/cid/cis784 10.1002/ppul.22851 10.1186/1471-2334-13-591 10.1093/jac/dkr003 10.1111/j.1469-0691.2009.02968.x 10.1128/AAC.04308-14 10.1517/14740338.4.4.623 10.1128/AAC.48.12.4624-4630.2004 10.1128/JCM.01345-07 10.1016/j.bjid.2013.09.004 10.1128/AAC.00737-13 10.1186/1471-2334-12-126 10.1128/AAC.00048-13 10.1007/s10156-009-0715-7 10.1128/JCM.00440-08 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2017 Public Library of Science 2017 Ishiguro et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2017 Ishiguro et al 2017 Ishiguro et al |
| Copyright_xml | – notice: COPYRIGHT 2017 Public Library of Science – notice: 2017 Ishiguro et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2017 Ishiguro et al 2017 Ishiguro et al |
| CorporateAuthor | Hokkaido Pediatric Respiratory Infection Study Group |
| CorporateAuthor_xml | – name: Hokkaido Pediatric Respiratory Infection Study Group |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISR 3V. 7QG 7QL 7QO 7RV 7SN 7SS 7T5 7TG 7TM 7U9 7X2 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AEUYN AFKRA ARAPS ATCPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU D1I DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB. KB0 KL. L6V LK8 M0K M0S M1P M7N M7P M7S NAPCQ P5Z P62 P64 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PTHSS PYCSY RC3 7X8 5PM DOA |
| DOI | 10.1371/journal.pone.0173635 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Opposing Viewpoints Gale In Context: Science ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Nursing & Allied Health Database Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Meteorological & Geoastrophysical Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Agricultural Science Collection Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database (ProQuest) Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Journals Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Materials Science & Engineering Collection ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland Advanced Technologies & Aerospace Collection Agricultural & Environmental Science Collection ProQuest Central Essentials - QC Biological Science Collection ProQuest Central Technology Collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One ProQuest Materials Science Collection ProQuest Central Engineering Research Database Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Collection (ProQuest) ProQuest Health & Medical Complete (Alumni) Materials Science Database Nursing & Allied Health Database (Alumni Edition) Meteorological & Geoastrophysical Abstracts - Academic ProQuest Engineering Collection Biological Sciences Agricultural Science Database ProQuest Health & Medical Collection Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Engineering Database Nursing & Allied Health Premium Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Environmental Science Database Materials Science Collection ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Engineering Collection Environmental Science Collection Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Agricultural Science Database Publicly Available Content Database ProQuest Central Student ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Meteorological & Geoastrophysical Abstracts Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Advanced Technologies & Aerospace Collection Engineering Database Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Agricultural Science Collection ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Environmental Science Collection Entomology Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic Meteorological & Geoastrophysical Abstracts - Academic ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts ProQuest Engineering Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts Materials Science Database ProQuest Materials Science Collection ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Animal Behavior Abstracts Materials Science & Engineering Collection Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Agricultural Science Database Engineering Research Database MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) Medicine |
| DocumentTitleAlternate | Antibiotic efficacy against Mycoplasma pneumoniae pneumonia |
| EISSN | 1932-6203 |
| ExternalDocumentID | 1876804310 oai_doaj_org_article_347458c2fad14a0c91c5ced03926b7ca PMC5348022 4320518401 A485280813 28288170 10_1371_journal_pone_0173635 |
| Genre | Multicenter Study Journal Article Observational Study |
| GroupedDBID | --- 123 29O 2WC 53G 5VS 7RV 7X2 7X7 7XC 88E 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAUCC AAWOE AAYXX ABDBF ABIVO ABJCF ABUWG ACGFO ACIHN ACIWK ACPRK ACUHS ADBBV ADRAZ AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS APEBS ARAPS ATCPS BAWUL BBNVY BCNDV BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI BWKFM CCPQU CITATION CS3 D1I D1J D1K DIK DU5 E3Z EAP EAS EBD EMOBN ESX EX3 F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IEA IGS IHR IHW INH INR IOV IPY ISE ISR ITC K6- KB. KQ8 L6V LK5 LK8 M0K M1P M48 M7P M7R M7S M~E NAPCQ O5R O5S OK1 OVT P2P P62 PATMY PDBOC PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO PTHSS PV9 PYCSY RNS RPM RZL SV3 TR2 UKHRP WOQ WOW ~02 ~KM 3V. BBORY CGR CUY CVF ECM EIF IPNFZ NPM RIG PMFND 7QG 7QL 7QO 7SN 7SS 7T5 7TG 7TM 7U9 7XB 8FD 8FK AZQEC C1K DWQXO FR3 GNUQQ H94 K9. KL. M7N P64 PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS RC3 7X8 5PM PUEGO - 02 AAPBV ABPTK ADACO BBAFP KM |
| ID | FETCH-LOGICAL-c835t-1709f9e7d4d75f3834ed8768364e8fdb81aaff5e42d7de665d62c9cd9dc6c533 |
| IEDL.DBID | M48 |
| ISSN | 1932-6203 |
| IngestDate | Fri Nov 26 17:22:38 EST 2021 Wed Aug 27 01:31:31 EDT 2025 Thu Aug 21 18:28:43 EDT 2025 Fri Jul 11 10:35:50 EDT 2025 Mon Jul 21 09:47:01 EDT 2025 Fri Jul 25 10:35:00 EDT 2025 Tue Jun 17 20:58:42 EDT 2025 Tue Jun 10 20:30:17 EDT 2025 Fri Jun 27 05:09:26 EDT 2025 Fri Jun 27 04:00:10 EDT 2025 Thu May 22 21:15:56 EDT 2025 Wed Feb 19 02:08:36 EST 2025 Thu Apr 24 23:12:39 EDT 2025 Tue Jul 01 01:43:20 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Language | English |
| License | This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Creative Commons Attribution License |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c835t-1709f9e7d4d75f3834ed8768364e8fdb81aaff5e42d7de665d62c9cd9dc6c533 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 Conceptualization: NI.Formal analysis: KO.Funding acquisition: NI.Investigation: NK MK AH TK.Methodology: NI.Resources: KM NN MN KHara KHazama TW TY SSasaki HF MS SShida AI YT HA HN.Supervision: TA HK TT.Validation: MY.Writing – original draft: NI. Competing Interests: This research was funded in part by a Grant-in-Aid for Scientific Research (C), 2013 (25461577), from the Ministry of Education, Science, Sports and Culture of Japan and by a Health Science Research Grant (H24-Shinkou-Ippan-014) for Research on Emerging and Re-emerging Infectious Diseases, Labour and Welfare Programs from the Ministry of Health, Labour and Welfare of Japan. Pfizer Inc. provided grants for this study (A Prospective Observational Study of Antibiotic Treatment against Macrolide-Resistant Mycoplasma Pneumoniae Infections in Pediatric Patients, WS2419287) but was not involved in the design of the study or in enrollment of patients, data collection, analysis and interpretation, or preparation of the manuscript. We have declared that no competing interests exist along with any other relevant declarations relating to employment, consultancy, patents, products in development, marketed products, etc. This does not alter our adherence to PLOS ONE policies on sharing data and materials. Membership of Hokkaido Pediatric Respiratory Infection Study Group is provided in the Acknowledgments. |
| ORCID | 0000-0001-8594-6345 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1371/journal.pone.0173635 |
| PMID | 28288170 |
| PQID | 1876804310 |
| PQPubID | 1436336 |
| PageCount | e0173635 |
| ParticipantIDs | plos_journals_1876804310 doaj_primary_oai_doaj_org_article_347458c2fad14a0c91c5ced03926b7ca pubmedcentral_primary_oai_pubmedcentral_nih_gov_5348022 proquest_miscellaneous_1881762712 proquest_miscellaneous_1877525657 proquest_journals_1876804310 gale_infotracmisc_A485280813 gale_infotracacademiconefile_A485280813 gale_incontextgauss_ISR_A485280813 gale_incontextgauss_IOV_A485280813 gale_healthsolutions_A485280813 pubmed_primary_28288170 crossref_primary_10_1371_journal_pone_0173635 crossref_citationtrail_10_1371_journal_pone_0173635 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2017-03-13 |
| PublicationDateYYYYMMDD | 2017-03-13 |
| PublicationDate_xml | – month: 03 year: 2017 text: 2017-03-13 day: 13 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: San Francisco – name: San Francisco, CA USA |
| PublicationTitle | PloS one |
| PublicationTitleAlternate | PLoS One |
| PublicationYear | 2017 |
| Publisher | Public Library of Science Public Library of Science (PLoS) |
| Publisher_xml | – name: Public Library of Science – name: Public Library of Science (PLoS) |
| References | Z Zhou (ref9) 2015; 59 (ref29) 2011 F Zhao (ref12) 2013; 57 S Nakazawa (ref33) 1972; 25 H Komatsu (ref23) 2014; 18 Y Kawai (ref24) 2012; 17 A Eshaghi (ref6) 2013 Y Kawai (ref14) 2013; 57 M Matsuoka (ref31) 2004; 48 E Naline (ref34) 1991; 32 Y Zhou (ref21) 2014; 58 K Matsuda (ref13) 2013; 13 Z Ma (ref10) 2014; 49 N Okazaki (ref3) 2001; 45 N Miyashita (ref22) 2013; 57 AR Sanchez (ref27) 2004; 43 N Principi (ref1) 2013; 68 S Suzuki (ref19) 2006; 50 X Liu (ref11) 2014; 2014 R Dumke (ref7) 2010; 16 M Nasu (ref36) 1988; 36 KB Waites (ref2) 2004; 17 N Ishiguro (ref16) 2015 X Li (ref4) 2009; 28 L Hayflick (ref32) 1965; 23 H Sakata (ref25) 2012; 65 RW Grady (ref28) 2005; 4 PM Meyer Sauteur (ref18) 2016; 7 N Miyashita (ref15) 2012; 12 T Okada (ref26) 2012; 55 JM Winchell (ref30) 2008; 46 S Pereyre (ref5) 2007; 45 K Matsubara (ref20) 2009; 15 M Chironna (ref8) 2011; 66 K Sunakawa (ref35) 2010; 58 Y Kawai (ref17) 2013; 57 |
| References_xml | – volume: 17 start-page: 697 issue: 4 year: 2004 ident: ref2 article-title: Mycoplasma pneumoniae and its role as a human pathogen publication-title: Clinical microbiology reviews doi: 10.1128/CMR.17.4.697-728.2004 – volume: 32 start-page: 402 issue: 3 year: 1991 ident: ref34 article-title: Penetration of minocycline into lung tissues publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.1991.tb03920.x – volume: 57 start-page: 4046 issue: 8 year: 2013 ident: ref17 article-title: Nationwide surveillance of macrolide-resistant Mycoplasma pneumoniae infection in pediatric patients publication-title: Antimicrobial agents and chemotherapy doi: 10.1128/AAC.00663-13 – volume: 65 start-page: 173 issue: 3 year: 2012 ident: ref25 article-title: Clinical efficacy of tosufloxacin in children with pneumonia due to Mycoplasma pneumoniae publication-title: The Japanese journal of antibiotics – volume: 58 start-page: 1034 issue: 2 year: 2014 ident: ref21 article-title: More complications occur in macrolide-resistant than in macrolide-sensitive Mycoplasma pneumoniae pneumonia publication-title: Antimicrobial agents and chemotherapy doi: 10.1128/AAC.01806-13 – volume: 45 start-page: 617 issue: 8 year: 2001 ident: ref3 article-title: Characteristics of macrolide-resistant Mycoplasma pneumoniae strains isolated from patients and induced with erythromycin in vitro publication-title: Microbiology and immunology doi: 10.1111/j.1348-0421.2001.tb01293.x – volume: 2014 start-page: 320801 year: 2014 ident: ref11 article-title: Drug resistance mechanisms of Mycoplasma pneumoniae to macrolide antibiotics publication-title: BioMed research international – volume: 57 start-page: 1521 issue: 3 year: 2013 ident: ref12 article-title: Surveillance of macrolide-resistant Mycoplasma pneumoniae in Beijing, China, from 2008 to 2012 publication-title: Antimicrobial agents and chemotherapy doi: 10.1128/AAC.02060-12 – volume: 7 start-page: 329 year: 2016 ident: ref18 article-title: Infection with and Carriage of Mycoplasma pneumoniae in Children publication-title: Front Microbiol doi: 10.3389/fmicb.2016.00329 – volume: 58 start-page: 69 issue: S-2 year: 2010 ident: ref35 article-title: Population pharmacokinetics and pharmacodynamics of tosufloxacin granules in pediatric infectious diseases publication-title: Jpn J Chemother – year: 2015 ident: ref16 article-title: Regional Differences in Rates of Macrolide-Resistant Mycoplasma pneumoniae in Hokkaido, Japan publication-title: Japanese journal of infectious diseases – volume: 17 start-page: 354 issue: 2 year: 2012 ident: ref24 article-title: Clinical efficacy of macrolide antibiotics against genetically determined macrolide-resistant Mycoplasma pneumoniae pneumonia in paediatric patients publication-title: Respirology doi: 10.1111/j.1440-1843.2011.02102.x – volume: 68 start-page: 506 issue: 3 year: 2013 ident: ref1 article-title: Macrolide-resistant Mycoplasma pneumoniae: its role in respiratory infection publication-title: The Journal of antimicrobial chemotherapy doi: 10.1093/jac/dks457 – volume: 28 start-page: 693 issue: 8 year: 2009 ident: ref4 article-title: Emerging macrolide resistance in Mycoplasma pneumoniae in children: detection and characterization of resistant isolates publication-title: The Pediatric infectious disease journal doi: 10.1097/INF.0b013e31819e3f7a – volume: 43 start-page: 709 issue: 10 year: 2004 ident: ref27 article-title: Tetracycline and other tetracycline-derivative staining of the teeth and oral cavity publication-title: Int J Dermatol doi: 10.1111/j.1365-4632.2004.02108.x – volume: 36 start-page: 699 issue: S-9 year: 1988 ident: ref36 article-title: -3262 in respiratory tract infections publication-title: T – volume: 50 start-page: 709 issue: 2 year: 2006 ident: ref19 article-title: Clinical evaluation of macrolide-resistant Mycoplasma pneumoniae publication-title: Antimicrobial agents and chemotherapy doi: 10.1128/AAC.50.2.709-712.2006 – volume: 55 start-page: 1642 issue: 12 year: 2012 ident: ref26 article-title: Rapid effectiveness of minocycline or doxycycline against macrolide-resistant Mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children publication-title: Clinical infectious diseases: an official publication of the Infectious Diseases Society of America doi: 10.1093/cid/cis784 – volume: 49 start-page: 695 issue: 7 year: 2014 ident: ref10 article-title: Characterization of macrolide resistance of Mycoplasma pneumoniae in children in Shenzhen, China publication-title: Pediatric pulmonology doi: 10.1002/ppul.22851 – volume: 13 start-page: 591 year: 2013 ident: ref13 article-title: Gene and cytokine profile analysis of macrolide-resistant Mycoplasma pneumoniae infection in Fukuoka, Japan publication-title: BMC infectious diseases doi: 10.1186/1471-2334-13-591 – year: 2011 ident: ref29 article-title: Guidelines for the management of respiratory infectious diseases in children in Japan – volume: 25 start-page: 288 issue: 5 year: 1972 ident: ref33 article-title: Effects of dry syrup minocycline (Minomycin 'Lederle') in the pediatric field publication-title: The Japanese journal of antibiotics – volume: 66 start-page: 734 issue: 4 year: 2011 ident: ref8 article-title: Emergence of macrolide-resistant strains during an outbreak of Mycoplasma pneumoniae infections in children publication-title: The Journal of antimicrobial chemotherapy doi: 10.1093/jac/dkr003 – volume: 16 start-page: 613 issue: 6 year: 2010 ident: ref7 article-title: Occurrence of macrolide-resistant Mycoplasma pneumoniae strains in Germany publication-title: Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases doi: 10.1111/j.1469-0691.2009.02968.x – volume: 59 start-page: 1048 issue: 2 year: 2015 ident: ref9 article-title: Macrolide-Resistant Mycoplasma pneumoniae in Adults in Zhejiang, China publication-title: Antimicrobial agents and chemotherapy doi: 10.1128/AAC.04308-14 – volume: 4 start-page: 623 issue: 4 year: 2005 ident: ref28 article-title: Systemic quinolone antibiotics in children: a review of the use and safety publication-title: Expert Opin Drug Saf doi: 10.1517/14740338.4.4.623 – volume: 48 start-page: 4624 issue: 12 year: 2004 ident: ref31 article-title: Characterization and molecular analysis of macrolide-resistant Mycoplasma pneumoniae clinical isolates obtained in Japan publication-title: Antimicrobial agents and chemotherapy doi: 10.1128/AAC.48.12.4624-4630.2004 – volume: 45 start-page: 3534 issue: 11 year: 2007 ident: ref5 article-title: First report of macrolide-resistant strains and description of a novel nucleotide sequence variation in the P1 adhesin gene in Mycoplasma pneumoniae clinical strains isolated in France over 12 years publication-title: Journal of clinical microbiology doi: 10.1128/JCM.01345-07 – start-page: 19 year: 2013 ident: ref6 article-title: Macrolide-resistant Mycoplasma pneumoniae in humans, Ontario, Canada, 2010–2011 publication-title: Emerging infectious diseases – volume: 18 start-page: 294 issue: 3 year: 2014 ident: ref23 article-title: Characteristics of hospitalized children infected with macrolide-resistant Mycoplasma pneumoniae publication-title: The Brazilian journal of infectious diseases: an official publication of the Brazilian Society of Infectious Diseases doi: 10.1016/j.bjid.2013.09.004 – volume: 57 start-page: 5181 issue: 10 year: 2013 ident: ref22 article-title: Macrolide-resistant Mycoplasma pneumoniae pneumonia in adolescents and adults: clinical findings, drug susceptibility, and therapeutic efficacy publication-title: Antimicrobial agents and chemotherapy doi: 10.1128/AAC.00737-13 – volume: 12 start-page: 126 year: 2012 ident: ref15 article-title: Macrolide-resistant Mycoplasma pneumoniae in adolescents with community-acquired pneumonia publication-title: BMC infectious diseases doi: 10.1186/1471-2334-12-126 – volume: 57 start-page: 2252 issue: 5 year: 2013 ident: ref14 article-title: Therapeutic Efficacy of Macrolides, Minocycline, and Tosufloxacin against Macrolide-Resistant Mycoplasma pneumoniae Pneumonia in Pediatric Patients publication-title: Antimicrobial agents and chemotherapy doi: 10.1128/AAC.00048-13 – volume: 15 start-page: 380 issue: 6 year: 2009 ident: ref20 article-title: A comparative clinical study of macrolide-sensitive and macrolide-resistant Mycoplasma pneumoniae infections in pediatric patients publication-title: Journal of infection and chemotherapy: official journal of the Japan Society of Chemotherapy doi: 10.1007/s10156-009-0715-7 – volume: 46 start-page: 3116 issue: 9 year: 2008 ident: ref30 article-title: Evaluation of three real-time PCR assays for detection of Mycoplasma pneumoniae in an outbreak investigation publication-title: Journal of clinical microbiology doi: 10.1128/JCM.00440-08 – volume: 23 start-page: 285 issue: Suppl 1 year: 1965 ident: ref32 article-title: Tissue cultures and mycoplasmas publication-title: Texas reports on biology and medicine |
| SSID | ssj0053866 |
| Score | 2.4503567 |
| Snippet | To clarify therapeutic effects of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae (MRMP) pneumonia... Objective To clarify therapeutic effects of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae (MRMP)... OBJECTIVE:To clarify therapeutic effects of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae (MRMP)... Objective To clarify therapeutic effects of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae (MRMP)... |
| SourceID | plos doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e0173635 |
| SubjectTerms | Adolescent Analysis Anti-Bacterial Agents - pharmacology Anti-Bacterial Agents - therapeutic use Antibiotics Antimicrobial agents Azithromycin Azithromycin - therapeutic use Bacteriology Biology and Life Sciences Chemotherapy Child Children Clarithromycin Clarithromycin - therapeutic use Dosage and administration Drug Resistance, Bacterial - drug effects Drug therapy Female Fever Fluoroquinolones - therapeutic use Health aspects Hospitals Humans Infections Infectious diseases Informed consent Male Medicine Medicine and Health Sciences Microbial Sensitivity Tests Minocycline Minocycline - therapeutic use Mycoplasma pneumonia Mycoplasma pneumoniae Mycoplasma pneumoniae - drug effects Mycoplasma pneumoniae - genetics Naphthyridines - therapeutic use Observational studies Patients Pediatrics Physical Sciences Pneumonia Pneumonia, Mycoplasma - drug therapy Pneumonia, Mycoplasma - etiology Tosufloxacin Treatment Outcome University graduates |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db5RAEN-Ye_LFWL-KXnU1JmoiLSzLAo_V2FSTaqKn6RtZZpdKcgdE7pKef5t_nDPAcYdprA--cexAuJ2P_S3M_Iax55lQlgip3QwAXCmyDONg5rsio5cCAvJQUjXy2Ud1-lV-OA_Pd1p9UU5YRw_cTdxRICMZxiBybXypPUh8CMEaD9d1lUXQQiNc8zabqS4Goxcr1RfKBZF_1OvlsK5Ke4g2GKi2vdt2IWr5-oeoPKnnVXMV5Pwzc3JnKTq5zW71GJIfd8--x27Y8g7b67204S97KulXd9mv2ba8iltii9Cw5lXO9c-CGiQs1lCUrzng9nb396IoK1hT0aTlujR8WTWrfF5dahzl-kIXiCn5QgN1_DHWxR07odBy2QpvzzeUHE_hlJ-toaoRpy80r0u7QtMvtN0ecrxtvekZwnuq1-Yem528m709dft-DS4gjlu6fuQleWIjI00U5rj1ldZgsI0DJW2cmyz2tc7z0EphImOVCo0SkIBJDChA2HmfTUpU0D7jCFoFmo0nTWBkaLwsCayXKWEh8RLwPYcFG92l0HOZU0uNedp-oItwT9OpIiWNp73GHeYOV9Udl8c18m_ILAZZYuJuT6B9pr19ptfZp8OekFGlXVnrEE_SYxmHgtqeBA571koQG0dJ6T4XetU06ftP3_5B6MvnkdCLXiivcDrQpLoSC_xPxPI1kpyOJDGmwGh4n1xgMytN6pMeiYcJp366cYurh58Ow3RTSuErbbVqZaJQ0Ff2v8nEPq7OkS8c9qDztGH26d0AsUk6LBr54Eg945Gy-N4SpoeBpIryh_9Dn4_YTUHIjlI6gymbLH-s7AHi0mX2uA1BvwEcIpNJ priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3fb9MwELagSIgXxMaPBQYYhARIZEscx06e0EBMA6kgQUF7ixzbKZXaJCytRPnb-OO4S9x0QdPgrY0_R63Pdz7bd98R8ixnwiIhtZ9rrX3O8hzsYB76LMdDAaaLmGM28vijOPnKP5zGp-7ArXFhlRub2BpqU2k8Iz8MQW0TZIIJXtc_fKwahberroTGVXINqcswpEue9hsu0GUhXLpcJMNDJ52DuirtAczESLRF3rbLUcva39vmUT2vmoscz7_jJ88tSMe3yE3nSdKjTvQ75Iotd8n1sbsr3yU7Tm0b-sJxS7-8TX5PtvlW1CJ9hNJrWhVU_ZphxYTFGjq_ohr2u-e_L2ZlpdeYRWmpKg1dVs2qmFc_FbRSNVUzcDLpQmksAWSsD1t4dEvLZQvePm8wWh7tKx2vdVWD475QtC7tCgZ3puz2I4XX1psiItRxvzZ3yOT43eTtie8KOPgaHLulH8ogLVIrDTcyLmAvzK1BMUaC26QweRIqVRSx5cxIY4WIjWA61SY1WmjwQ--SUQmy2iMUvFgG8yjgJjI8NkGeRjbIBbM6DVIdBh6JNmLMtCM3xxob86y9sZOwyemkkqHwMyd8j_h9r7oj9_gH_g3OkB6L1Nztg-psmjlNzyIueZxoVigTchXoNNSxtiYAR1TkUiuPPMb5lXV5rr2ByY54EjOsgxJ55GmLQHqOEuN_pmrVNNn7T9_-A_Tl8wD03IGKCoYDplSXcwH_CWm_Bsj9ARKMjB4076E2bEalybbqCD03GnJx85O-GV-KMX2lrVYtRsYMr90vwyQhLNcyZB651yldP_p4WID0kh6RA3UciGfYUs6-twzqccQxxfz-5T_9AbnB0InD6M1on4yWZyv7EFzQZf6otTN_ABETjZs priority: 102 providerName: ProQuest |
| Title | Therapeutic efficacy of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant and macrolide-sensitive Mycoplasma pneumoniae pneumonia in pediatric patients |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/28288170 https://www.proquest.com/docview/1876804310 https://www.proquest.com/docview/1877525657 https://www.proquest.com/docview/1881762712 https://pubmed.ncbi.nlm.nih.gov/PMC5348022 https://doaj.org/article/347458c2fad14a0c91c5ced03926b7ca http://dx.doi.org/10.1371/journal.pone.0173635 |
| Volume | 12 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELe2TkK8IDY-VijFICRAIlXiOHHygNA2dQykDjQ61LfIsZ1SqU1K00orD_xl_HHcpWm6oA54sdr4HCn35fPH_Y6QFzHzDQJSW7FSyuIsjsEPxo7FYtwUYCrxOGYj9879s0v-ceANdsi6ZmvJwHzr0g7rSV3Oxp2r78t3YPBvi6oNwlkP6kyz1HRAw1yYRHfJHsxNAk21x6tzBbBu3y8T6G4aWZugChz_yls3puMs3xaK_nmj8toUdXqX3CljS3q0UoZ9smPSA3KrV56eH5D90pBz-qpEm359j_zqbzKwqEFACamWNEuo_DHCGgqTJQx-QxWw6fr_ySjN1BLzKg2VqabzLF8k4-xKQi-VQzmCsJNOpMKiQNpYsKjHQDWdF8Sb5znen0ePS3tLlU0hlJ9IOk3NAqxjJM3mJ4XXTtdlRWiJBpvfJ_3Tbv_kzCpLOlgKQr255Qg7TEIjNNfCS2B1zI0Gfxy4PjdBouPAkTJJPMOZFtr4vqd9pkKlQ618BZHpA9JIQVaHhEJcy0CzbK5dzT1tx6Fr7NhnRoV2qBy7Sdy1GCNVwp1j1Y1xVJzhCVj2rKQSofCjUvhNYlWjpiu4j3_QH6OGVLQI1l08yGbDqLT9yOWCe4FiidQOl7YKHeUpo20ITf1YKNkkT1G_olXma-VyoiMeeAwro7hN8rygQMCOFG8EDeUiz6MPn77-B9GXixrRy5IoyYAdoFKrLAz4JgQCq1G2apTgdlSt-xCtYc2VPHJQjgjVBKxvrS1ke_ezqhtfirf8UpMtChrhMTyI_xtN4MAELhzWJA9XRldxH7cPEHCySUTNHGviqfeko28Fprrnckw6f3TzVz0mtxmGdHiX022Rxny2ME8gIJ3HbbIrBgLa4MTB9vR9m-wdd88_X7SLLZ524YOw_dn9DdE_mAA |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLamIgEviI3LCoMZBAIksiWOc3tAaFymlq1Dgg71LXJsp1Rqk9C0gvKf-Af8OM7JrQuaBi97a-NjK_G5-Bzb5zuEPImYqxGQ2oiklAZnUQR2MLIMFuGmAJOxwzEbeXDi9k75h5Ez2iC_6lwYvFZZ28TCUKtU4h75vgVq6yMSjPk6-2Zg1Sg8Xa1LaJRicaRX3yFky1_13wF_nzJ2-H74tmdUVQUMCd7GwrA8M4gD7SmuPCeGAI1rhWPbLtd-rCLfEiKOHc2Z8pR2XUe5TAZSBUq60sH9T7D4V_BFUKG8URPfgelw3So7z_as_UoY9rI00Xsg-LZb1JRbr35FkYBmKehk0zQ_z8_9-7rmmfXv8Ca5UTmu9KCUtE2yoZMtcnVQHc1vkc3KSuT0eQVl_eIW-T1cp3dRjWgVQq5oGlPxc4IFGmYr6PySSgivz_6fTZJUrjBpU1ORKLpI82U8TX8IaKViLCbg09KZkFhxSGljrnP0gpNFQbx-nuPlfDTndLCSaQZxwkzQLNFL4OVE6PVPCsNmdc0SWkHN5rfJ8DI4e4d0EuDVNqHgNDMQW5MrW3FHmVFgazNymZaBGUjL7BK7ZmMoKyx1LOkxDYsDQg9iqpIrITI_rJjfJUbTKyuxRP5B_wYlpKFFJPDiQTofh5VhCW3ucceXLBbK4sKUgSUdqZUJfq8beVJ0yS7KV1im1Tb2LDzgvsOw7IrdJY8LCkQDSfC60Vgs8zzsf_zyH0SfP7WInlVEcQrTASJVpnjANyHKWItyp0UJNk22mrdRG-pZycO19kPPWkPOb37UNOOgeIUw0emyoPEchqf8F9H4FngHnsW65G6pdM3s494Eoll2iddSxxZ72i3J5GsB2O7YHDPa71386rvkWm84OA6P-ydH98l1hv4jXhy1d0hnMV_qB-D9LqKHhc2hJLxkG_cHpeXK_g |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELemIU28IDY-VhjMIBAgkS1xnLh5QGgwqo2xgaCgvUWO7YxKaxKaVlD-MyT-OO4SJ13QNHjZWxtfktZ39_OdfR-EPEpYaLAgtZMopRzOkgRwMPEcluCmAFNpwDEb-fAo3PvM3x4Hx0vkV5MLg2GVDSZWQK1zhXvk2x6obR8rwbjbqQ2L-LA7eFl8c7CDFJ60Nu00ahE5MPPv4L6VL_Z3gdePGRu8Gb7ec2yHAUeB5TF1POFGaWSE5loEKThr3Gh8jx9y00910vekTNPAcKaFNmEY6JCpSOlIq1AFuBcK6H9F-IGHKiaOW18PYCQMbaaeL7xtKxhbRZ6ZLVACP6z6yy1WwqphQLssLBeneXmezft36OaZtXBwnVyzRizdqaVulSyZbI2sHNpj-jWyahGjpE9tWetnN8jv4SLVixqsXCHVnOYplT9H2KxhPIebn1MFrvbZ7-NRlqs5JnAaKjNNp3k5S0_zHxJGqTyRI7Bv6Vgq7D6kjTMxJVrE2bQiXlwvMVAfoZ0ezlVegM8wlrTIzAx4OZJm8ZHCY4umfwm1ZWfLm2R4GZy9RZYz4NU6oWBAMxBhl2tf80C7SeQbNwmZUZEbKc_tEb9hY6xsXXVs73EaV4eFAvyrmisxMj-2zO8Rp72rqOuK_IP-FUpIS4tVwasL-eQktiAT-1zwoK9YKrXHpasiTwXKaBds4DARSvbIJspXXKfYttgW7_B-wLAFi98jDysKrAySoY6dyFlZxvvvv_wH0aePHaInlijNYTpApOp0D_hPWHGsQ7nRoQR8U53hddSGZlbKeIEEcGejIecPP2iH8aEYTpiZfFbRiIDhif9FNH0PLAXhsR65XStdO_u4T4GVLXtEdNSxw57uSDb6WhVvD3yO2e13Lv7pm2QF0C1-t390cJdcZWhKYgypv0GWp5OZuQeG8DS5X0EOJfElQ9wf4ZXPNA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Therapeutic+efficacy+of+azithromycin%2C+clarithromycin%2C+minocycline+and+tosufloxacin+against+macrolide-resistant+and+macrolide-sensitive+Mycoplasma+pneumoniae+pneumonia+in+pediatric+patients&rft.jtitle=PloS+one&rft.au=Ishiguro%2C+Nobuhisa&rft.au=Koseki%2C+Naoko&rft.au=Kaiho%2C+Miki&rft.au=Ariga%2C+Tadashi&rft.date=2017-03-13&rft.pub=Public+Library+of+Science&rft.eissn=1932-6203&rft.volume=12&rft.issue=3&rft_id=info:doi/10.1371%2Fjournal.pone.0173635&rft.externalDocID=1876804310 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon |